ATLANTA, GA – – (July 25, 2022) – – Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX). The lawsuit alleges TG Therapeutics made false and/or misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and compliance policies, including: (i) clinical trials revealed significant concerns regarding the benefit-risk ratio and overall survival data of two therapies, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely TG Therapeutics would obtain FDA approval for several of its New Drug Applications or Biologics License Applications for those therapies; (iii) as a result, the Company had significantly overstated the clinical and/or commercial prospects of those therapies.
If you bought shares of TG Therapeutics between January 15, 2020 and May 31, 2022, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is September 16, 2022.
Lead Plaintiff Deadline Has Passed
September 16, 2022